Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Mahlangu JN"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-18 z 18
    Tytuł:
    Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa
    Autorzy:
    Nalado AM
    Mahlangu JN
    Waziri B
    Duarte R
    Paget G
    Olorunfemi G
    Naicker S
    Pokaż więcej
    Temat:
    anaemia
    predictors
    chronic kidney disease
    haemoglobin
    risk factors
    iron deficiency anaemia
    Diseases of the genitourinary system. Urology
    RC870-923
    Źródło:
    International Journal of Nephrology and Renovascular Disease, Vol Volume 12, Pp 19-32 (2019)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/ethnic-prevalence-of-anemia-and-predictors-of-anemia-among-chronic-kid-peer-reviewed-article-IJNRD; https://doaj.org/toc/1178-7058
    Dostęp URL:
    https://doaj.org/article/93d7181995d248309644a62597c370a6  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies.
    Autorzy:
    Parnes A; Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
    Mahlangu JN; University of the Witwatersrand and NHLS, Johannesburg, South Africa.
    Pipe SW; University of Michigan, Ann Arbor, Michigan, USA.
    Paz-Priel I; Genentech, Inc., South San Francisco, California, USA.
    Lehle M; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    Trask PC; Genentech, Inc., South San Francisco, California, USA.
    Jiménez-Yuste V; La Paz University Hospital, Autónoma University, Madrid, Spain.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. e772-e775. Date of Electronic Publication: 2021 Oct 08.
    Typ publikacji:
    Letter
    MeSH Terms:
    Antibodies, Bispecific*
    Hemophilia A*/drug therapy
    Antibodies, Monoclonal, Humanized/therapeutic use ; Factor VIII ; Humans ; Patient Preference
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Autorzy:
    Oldenburg J; Department of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
    Tran H; The Alfred Hospital, Melbourne, Vic., Australia.
    Peyvandi F; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Fondazione Ca, Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
    Núñez R; Hospital Universitario Virgen Del Rocio, Seville, Spain.
    Trask P; Genentech, Inc., South San Francisco, CA, USA.
    Chebon S; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.
    Lehle M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    Jiménez-Yuste V; La Paz University Hospital, Autónoma University, Madrid, Spain.
    von Mackensen S; Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. 398-407. Date of Electronic Publication: 2021 Feb 12.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hemophilia A*/drug therapy
    Quality of Life*
    Adolescent ; Adult ; Aged ; Child ; Factor VIII/therapeutic use ; Health Status ; Humans ; Infant, Newborn ; Middle Aged ; Surveys and Questionnaires ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
    Autorzy:
    Kempton C; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
    Trask P; Genentech, Inc., South San Francisco, CA, USA.
    Parnes A; Brigham and Women's Hospital, Boston, MA, USA.
    Niggli M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    Campinha-Bacote A; Genentech, Inc., South San Francisco, CA, USA.
    U Callaghan M; Children's Hospital of Michigan, Detroit, MI, USA.
    O'Connell N; St James's Hospital, Dublin, Ireland.
    Paz-Priel I; Genentech, Inc., South San Francisco, CA, USA.
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Mar; Vol. 27 (2), pp. 221-228. Date of Electronic Publication: 2021 Jan 28.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antibodies, Bispecific*
    Hemophilia A*/drug therapy
    Antibodies, Monoclonal, Humanized ; Factor VIII/therapeutic use ; Hemorrhage ; Humans ; Personal Satisfaction ; Surveys and Questionnaires
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Redefining prophylaxis in the modern era.
    Autorzy:
    Mahlangu JN; Faculty of Health Sciences, Haemophilia Comprehensive Care, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and the NHLS, Johannesburg, South Africa.
    Blanchette V; Department of Pediatrics, Division of Hematology/Oncology Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
    Klamroth R; Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Feb; Vol. 27 Suppl 3, pp. 21-27. Date of Electronic Publication: 2020 May 29.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hemophilia A*/drug therapy
    Humans ; Factor VIII/therapeutic use ; Hemorrhage/prevention & control ; Hemostasis ; Quality of Life ; Review Literature as Topic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Requirements to participate in haemophilia clinical trials.
    Autorzy:
    Mahlangu JN; Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Parktown, South Africa.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2020 Apr; Vol. 26 Suppl 3, pp. 22-25.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hemophilia A/*diagnosis
    Clinical Trials as Topic ; Humans ; Research Design
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Autorzy:
    Oldenburg J; Department of Experimental Haematology and Transfusion Medicine, Universitätsklinikum University Clinic Bonn, Bonn, Germany.
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.
    Bujan W; Instituto de Costarricense de Investigaciones Científicas, San Jose, Costa Rica.
    Trask P; Genentech, Inc., South San Francisco, California.
    Callaghan MU; Children's Hospital of Michigan, Detroit Medical Center, Detroit, Michigan.
    Young G; Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
    Asikanius E; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
    Peyvandi F; IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
    Santagostino E; IRCCS Ca' Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy.
    Kruse-Jarres R; Washington Center for Bleeding Disorders at BloodWorks NW, University of Washington, Seattle, Washington.
    Negrier C; Louis Pradel University Hospital, Lyon, France.
    Kessler C; Georgetown University Medical Center, N.W., Washington, District of Columbia.
    Xu J; Genentech, Inc., South San Francisco, California.
    Windyga J; Department of Disorders of Hemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
    Shima M; Department of Pediatrics, Nara Medical University, Kashihara, Japan.
    von Mackensen S; University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2019 Jan; Vol. 25 (1), pp. 33-44. Date of Electronic Publication: 2018 Nov 14.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
    MeSH Terms:
    Quality of Life*
    Antibodies, Bispecific/*therapeutic use
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Hemophilia A/*drug therapy
    Isoantibodies/*blood
    Adolescent ; Adult ; Aged ; Child ; Factor VIII/antagonists & inhibitors ; Health Status ; Hospitalization ; Humans ; Male ; Middle Aged ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa.
    Autorzy:
    Nalado AM; Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.; Department of Internal Medicine, College of Health Sciences, Bayero University, Kano, Nigeria.
    Mahlangu JN; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
    Duarte R; Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
    Paget G; Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
    Olorunfemi G; Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
    Jacobson BF; Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
    Naicker S; Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2018 Oct 03; Vol. 13 (10), pp. e0204899. Date of Electronic Publication: 2018 Oct 03 (Print Publication: 2018).
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Erythrocyte Indices*
    Anemia, Iron-Deficiency/*diagnosis
    Biomarkers/*blood
    Hemoglobins/*metabolism
    Renal Insufficiency, Chronic/*complications
    Adult ; Aged ; Anemia, Iron-Deficiency/blood ; Anemia, Iron-Deficiency/etiology ; Cross-Sectional Studies ; Erythrocyte Count ; Female ; Ferritins/blood ; Humans ; Iron/blood ; Male ; Middle Aged ; Renal Insufficiency, Chronic/blood ; Renal Insufficiency, Chronic/ethnology ; Reticulocytes/metabolism ; Sensitivity and Specificity ; South Africa/ethnology ; Transferrin/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
    Autorzy:
    Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
    Kulkarni R; Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA.
    Srivastava A; Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa.
    Blanchette VS; Department of Pediatrics, University of Toronto and Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
    Tsao E; Bioverativ, Waltham, MA, USA.
    Winding B; Sobi, Stockholm, Sweden.
    Dumont J; Bioverativ, Waltham, MA, USA.
    Jain N; Bioverativ, Waltham, MA, USA.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2018 Jan; Vol. 24 (1), pp. 77-84. Date of Electronic Publication: 2017 Oct 30.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Factor VIII/*therapeutic use
    Hemophilia A/*drug therapy
    Immunoglobulin Fc Fragments/*therapeutic use
    Joints/*physiopathology
    Recombinant Fusion Proteins/*therapeutic use
    Adolescent ; Adult ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Hemophilia A/complications ; Hemophilia A/pathology ; Humans ; Joint Diseases/complications ; Joint Diseases/diagnosis ; Male ; Middle Aged ; Range of Motion, Articular ; Severity of Illness Index ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life.
    Autorzy:
    Young JE; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
    Grabell J; Department of Medicine, Queen's University, Kingston, ON, Canada.
    Tuttle A; Department of Medicine, Queen's University, Kingston, ON, Canada.
    Bowman M; Department of Medicine, Queen's University, Kingston, ON, Canada.
    Hopman WM; Department of Public Health Sciences, Queen's University, Kingston, ON, Canada.
    Good D; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
    Rydz N; Department of Medicine, University of Calgary, Calgary, AB, Canada.
    Mahlangu JN; Faculty of Health Sciences, Department of Molecular Medicine and Haematology, School of Pathology, University of Witwatersrand and the NHLS, Johannesburg, South Africa.
    James PD; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.; Department of Medicine, Queen's University, Kingston, ON, Canada.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2017 Nov; Vol. 23 (6), pp. e536-e538. Date of Electronic Publication: 2017 Sep 26.
    Typ publikacji:
    Evaluation Study; Letter
    MeSH Terms:
    Quality of Life*
    Hemophilia A/*complications
    Hemorrhage/*complications
    Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Self Report ; Surveys and Questionnaires ; Young Adult
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
    Autorzy:
    Shapiro AD; Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.
    Mahlangu JN; Faculty of Health Sciences, University of the Witwatersrand and NHLS Hospital, Parktown, Johannesburg, South Africa.
    Perry D; Addenbrookes Hospital, Cambridge, UK.
    Pasi J; Barts and The London Comprehensive Care Center, London, UK.
    Quon DV; Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA.
    Chowdary P; Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK.
    Tsao E; Biogen, Cambridge, MA, USA.
    Li S; Biogen, Cambridge, MA, USA.
    Innes A; Biogen, Cambridge, MA, USA.
    Pierce GF; Biogen, Cambridge, MA, USA.
    Allen GA; Biogen, Cambridge, MA, USA.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2017 May; Vol. 23 (3), pp. 392-399. Date of Electronic Publication: 2017 Feb 20.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article
    MeSH Terms:
    Factor VIII/*therapeutic use
    Hemophilia A/*complications
    Hemorrhage/*complications
    Hemorrhage/*drug therapy
    Immunoglobulin Fc Fragments/*genetics
    Recombinant Fusion Proteins/*therapeutic use
    Factor VIII/adverse effects ; Factor VIII/pharmacokinetics ; Female ; Hemophilia A/prevention & control ; Humans ; Male ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/pharmacokinetics ; Safety ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
    Autorzy:
    Mahlangu JN; Department of Molecular Medicine and Haematology, Faculty of Health Sciences, Haemophilia Comprehensive Care Centre, NHLS and University of the Witwatersrand, Johannesburg, South Africa.
    Andreeva TA; City Haemophilia Center, Saint Petersburg, Russia.
    Macfarlane DE; Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
    Walsh C; Mt Sinai School of Medicine, New York, NY, USA.
    Key NS; Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2017 Jan; Vol. 23 (1), pp. 33-41. Date of Electronic Publication: 2016 Oct 20.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Multicenter Study
    MeSH Terms:
    Hemophilia A/*drug therapy
    Hemorrhage/*drug therapy
    Adolescent ; Adult ; Animals ; Factor VIII/therapeutic use ; Female ; Humans ; Male ; Prospective Studies ; Swine ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Autorzy:
    Escobar MA; University of Texas Health Science Center and the Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA.
    Tehranchi R; Medical and Science, Haemophilia R&D Portfolio, Novo Nordisk A/S, Søborg, Denmark.
    Karim FA; National Blood Centre, Kuala Lumpur, Malaysia.
    Caliskan U; Department of Pediatric Hematology, NEU Meram Faculty of Medicine, Konya, Turkey.
    Chowdary P; Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK.
    Colberg T; Medical and Science, Haemophilia R&D Portfolio, Novo Nordisk A/S, Søborg, Denmark.
    Giangrande P; Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK.
    Giermasz A; Division of Hematology Oncology, University of California, San Francisco, CA, USA.
    Mancuso ME; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
    Serban M; Spitalul Clinic de Urgenta pentru Copii Louis Turcanu, IIIrd Paediatric Clinic, Timisoara, Romania.
    Tsay W; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
    Mahlangu JN; Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, NHLS and Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2017 Jan; Vol. 23 (1), pp. 67-76. Date of Electronic Publication: 2016 Aug 01.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    Factor IX/*therapeutic use
    Hemophilia B/*drug therapy
    Hemophilia B/*surgery
    Hemostatics/*therapeutic use
    Recombinant Proteins/*therapeutic use
    Adolescent ; Adult ; Aged ; Disease Management ; Humans ; Male ; Middle Aged ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Extended half-life clotting factor concentrates: results from published clinical trials.
    Autorzy:
    Young G; Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2016 Jul; Vol. 22 Suppl 5, pp. 25-30.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Factor IX/*pharmacokinetics
    Factor VIII/*pharmacokinetics
    Adolescent ; Adult ; Antibodies, Neutralizing/blood ; Child ; Factor IX/genetics ; Factor IX/therapeutic use ; Factor VIII/genetics ; Factor VIII/therapeutic use ; Half-Life ; Hemophilia A/drug therapy ; Hemophilia B/drug therapy ; Humans ; Immunoglobulin Fc Fragments/genetics ; Immunoglobulin Fc Fragments/metabolism ; Polyethylene Glycols/chemistry ; Recombinant Fusion Proteins/biosynthesis ; Recombinant Fusion Proteins/chemistry ; Recombinant Fusion Proteins/pharmacokinetics ; Serum Albumin/genetics ; Serum Albumin/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients.
    Autorzy:
    Lochan A; Division of Human Genetics, National Health Laboratory Service (NHLS) and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
    Macaulay S
    Chen WC
    Mahlangu JN
    Krause A
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2014 Sep; Vol. 20 (5), pp. 687-92. Date of Electronic Publication: 2014 Jun 21.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Blood Coagulation Factor Inhibitors/*blood
    Factor VIII/*genetics
    Hemophilia A/*genetics
    Adult ; Autoantibodies/blood ; Black People/genetics ; Factor VIII/antagonists & inhibitors ; Factor VIII/immunology ; Female ; Genetic Predisposition to Disease ; Haplotypes/genetics ; Hemophilia A/ethnology ; Hemophilia A/immunology ; Humans ; Male ; Middle Aged ; Mutation ; Retrospective Studies ; Risk Factors ; South Africa ; White People/genetics ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Assessment of outcomes.
    Autorzy:
    Blanchette VS; Division of Hematology/Oncology, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, ON, Canada.
    O'Mahony B
    McJames L
    Mahlangu JN
    Pokaż więcej
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2014 May; Vol. 20 Suppl 4, pp. 114-20.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Outcome Assessment, Health Care*
    Hemophilia A/*therapy
    Hemophilia B/*therapy
    Australia ; Capital Financing ; Humans ; Patient Satisfaction ; Physician's Role
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Haemophilia care in South Africa: 2004-2007 look back.
    Autorzy:
    Mahlangu JN; Haemophilia Comprehensive Care Centre, Johannesburg Hospital and Department of Molecular Medicine and Haematology, Faculty of Health Sciences, National Health Laboratory Services and University of the Witwatersrand, Johannesburg, South Africa.
    Pokaż więcej
    Corporate Authors:
    Medical and Scientific Council of the South African Haemophilia Foundation
    Źródło:
    Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2009 Jan; Vol. 15 (1), pp. 135-41. Date of Electronic Publication: 2008 Aug 12.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    Delivery of Health Care/*organization & administration
    Hemophilia A/*therapy
    Hemophilia B/*therapy
    Adult ; Child ; Drug Utilization/statistics & numerical data ; Factor IX/therapeutic use ; Factor VIII/therapeutic use ; Hemophilia A/epidemiology ; Hemophilia B/epidemiology ; Humans ; Male ; National Health Programs/organization & administration ; Program Evaluation ; Retrospective Studies ; South Africa/epidemiology ; Surgical Procedures, Operative/statistics & numerical data ; Workforce
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-18 z 18

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies